Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SNSS [NASD]
Sunesis Pharmaceuticals Inc.
Index- P/E- EPS (ttm)-0.66 Insider Own0.40% Shs Outstand60.10M Perf Week2.12%
Market Cap317.93M Forward P/E- EPS next Y-0.44 Insider Trans2.56% Shs Float59.61M Perf Month-23.00%
Income-34.60M PEG- EPS next Q-0.17 Inst Own82.80% Short Float10.15% Perf Quarter17.82%
Sales8.00M P/S39.74 EPS this Y27.50% Inst Trans0.83% Short Ratio6.95 Perf Half Y12.55%
Book/sh-0.11 P/B- EPS next Y21.40% ROA-69.20% Target Price11.83 Perf Year-3.99%
Cash/sh0.65 P/C8.09 EPS next 5Y- ROE828.70% 52W Range3.84 - 7.49 Perf YTD11.60%
Dividend- P/FCF- EPS past 5Y36.70% ROI-268.60% 52W High-29.37% Beta2.83
Dividend %- Quick Ratio1.20 Sales past 5Y8.20% Gross Margin- 52W Low37.76% ATR0.43
Employees32 Current Ratio1.20 Sales Q/Q0.00% Oper. Margin- RSI (14)39.21 Volatility6.19% 8.07%
OptionableYes Debt/Eq- EPS Q/Q-62.50% Profit Margin- Rel Volume0.31 Prev Close5.36
ShortableYes LT Debt/Eq- EarningsMay 05 Payout- Avg Volume870.40K Price5.29
Recom1.80 SMA20-11.80% SMA50-14.37% SMA2001.30% Volume272,139 Change-1.31%
11-Sep-12Reiterated Cantor Fitzgerald Buy $6 → $8
29-May-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
13-Apr-12Initiated Cantor Fitzgerald Buy $6
06-Mar-12Initiated Canaccord Genuity Buy $4
11-Oct-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
29-Sep-11Initiated MLV Capital Buy $3.50
22-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014 GlobeNewswire +8.16%
10-Apr-14 06:31PM  2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals at Motley Fool -8.75%
08-Apr-14 01:30PM  Sunesis vosaroxin shown to be effective, says Wedbush at theflyonthewall.com
11:00AM  Sunesis Pharmaceuticals Update Call to Discuss Poster Presented at the AACR Annual Meeting scheduled for 11:00 am ET today CCBN
08:00AM  Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS GlobeNewswire
07-Apr-14 11:17AM  Is Now the Time to Invest in Agios Pharmaceuticals, Inc? at Motley Fool
02-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014 GlobeNewswire +5.02%
31-Mar-14 07:04PM  Nasdaq stocks posting largest percentage decreases AP +5.93%
01:47PM  Nasdaq stocks posting largest percentage decreases AP
28-Mar-14 06:02PM  Nasdaq stocks posting largest percentage decreases AP -8.24%
24-Mar-14 04:03PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
12-Mar-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
06-Mar-14 02:40PM  Sunesis Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
02:40PM  Sunesis Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q4 2013 Sunesis Pharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
05-Mar-14 07:46AM  Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher Zacks
07:46AM  Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher
04-Mar-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials +6.76%
28-Feb-14 04:52PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:18AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
08:17AM  Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
27-Feb-14 06:42PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
08:44AM  Sunesis raises $43M in common stock and warrants offering theflyonthewall.com
08:30AM  Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants GlobeNewswire
26-Feb-14 04:13PM  Sunesis Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +5.33%
01:51PM  Nasdaq stocks posting largest percentage increases AP
25-Feb-14 06:02PM  Nasdaq stocks posting largest percentage increases AP +17.46%
01:28PM  Nasdaq stocks posting largest percentage increases AP
07:49AM  Sunesis risk/reward attractive at current levels, says Leerink theflyonthewall.com
19-Feb-14 04:01AM  3 Small Cap Biotechs Developing Novel Cancer Treatments at Motley Fool
11-Feb-14 07:33AM  Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% Zacks
10-Feb-14 08:01AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -5.42%
07:26AM  Sunesis announces vosaroxin Phase 3 VALOR trial unblinding expected in Q3 theflyonthewall.com
07:15AM  Sunesis (SNSS) Catches Eye: Stock Soars 18.3% Zacks
07:00AM  Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data GlobeNewswire
06-Feb-14 07:24AM  Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy? Zacks
07:05AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
17-Jan-14 03:52PM  Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week at TheStreet
09-Jan-14 11:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today CCBN
11:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today
11:00AM  Ingredion Incorporated Earnings Call scheduled for 11:00 am ET today CCBN
08:14AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today CCBN
07:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs
26-Dec-13 01:47AM  Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session Zacks
01:47AM  Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session
17-Dec-13 07:33AM  Sunesis Pharmaceuticals, Inc. is now in Oversold Territory Zacks
07:33AM  Sunesis Pharmaceuticals, Inc. is now in Oversold Territory
10-Dec-13 07:00AM  Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS GlobeNewswire
07:00AM  Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Trial Evaluating Vosaroxin in Combination With Azacitidine in MDS
03-Dec-13 10:38PM  Sunesis Pharmaceuticals' CEO Presents at the Piper Jaffray Healthcare Conference 2013 at Seeking Alpha
10:38PM  Sunesis Pharmaceuticals' CEO Presents at the Piper Jaffray Healthcare Conference 2013
27-Nov-13 07:00AM  Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference GlobeNewswire
07:00AM  Sunesis Pharmaceuticals to Present at the Piper Jaffray 25th Annual Healthcare Conference
20-Nov-13 01:05PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
01:05PM  SUNESIS PHARMACEUTICALS INC Financials
12-Nov-13 03:20PM  Sunesis Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript at Seeking Alpha
03:20PM  Sunesis Pharmaceuticals Management Discusses Q3 2013 Results - Earnings Call Transcript
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today
10:55AM  Sunesis Pharmaceuticals, Inc. Discusses Q3 2013 Results (Webcast) at Seeking Alpha
08:04AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q3 2013 Sunesis Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:03AM  InPlay: Sunesis Pharma beats by $0.04, beats on revs Briefing.com
07:00AM  Sunesis Pharmaceuticals Reports Third Quarter Financial Results and Recent Highlights GlobeNewswire
06-Nov-13 07:00AM  Sunesis to Present at the 2013 Credit Suisse Annual Health Care Conference GlobeNewswire
05-Nov-13 07:00AM  Sunesis to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Recent Highlights GlobeNewswire
30-Oct-13 07:00AM  Sunesis Pharmaceuticals Announces Initiation of Phase 2 Cohort of MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS GlobeNewswire
28-Oct-13 07:00AM  Sunesis Pharmaceuticals Announces Initiation of an Investigator-Sponsored Phase I/II Trial Evaluating Vosaroxin in Myelodysplastic Syndrome GlobeNewswire
27-Sep-13 12:11PM  Sunesis' CEO Presents at BioCentury's 2013 Newsmakers in the Biotech Industry Conference (Transcript) at Seeking Alpha
25-Sep-13 09:22AM  Sunesis Pharmaceuticals Completes Enrollment in Phase 3 VALOR Trial of Vosaroxin in AML GlobeNewswire
23-Sep-13 04:15PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
19-Sep-13 07:00AM  Sunesis to Present at BioCentury's 2013 Newsmakers in the Biotech Industry Conference GlobeNewswire
04-Sep-13 07:00AM  Sunesis to Present at the 2013 Stifel Nicolaus Healthcare Conference GlobeNewswire
09-Aug-13 01:17PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
07-Aug-13 07:00AM  Sunesis to Present at the 2013 Wedbush Life Sciences Management Access Conference GlobeNewswire
03-Aug-13 07:00PM  3 Horrendous Health-Care Stocks This Week at Motley Fool
02-Aug-13 04:54PM  SUNESIS PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report EDGAR Online
30-Jul-13 05:26PM  Why Sunesis Pharmaceuticals, Inc. Shares Slipped at Motley Fool
11:03AM  Sunesis slips after committee recommends ending study early at theflyonthewall.com
29-Jul-13 07:25PM  Sunesis Pharmaceuticals Earnings: Heres Why Investors are Selling Shares Now at Wall St. Cheat Sheet -6.61%
05:00PM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 5:00 pm ET today CCBN
04:01PM  Sunesis Pharmaceuticals Reports Second Quarter Financial Results and Recent Highlights GlobeNewswire
09:52AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
25-Jul-13 12:53PM  5 Stocks Under $10 Set to Soar at TheStreet +6.03%
24-Jul-13 08:22AM  4 Health Care Stocks Under $10 Close to Breakouts at TheStreet
15-Jul-13 06:06PM  Nasdaq stocks posting largest percentage decreases AP -5.53%
01:20PM  Nasdaq stocks posting largest percentage decreases AP
08-Jul-13 03:13PM  Why Sunesis Is Poised to Pull Back at Motley Fool
20-Jun-13 08:00AM  10 Most-Shorted Biotech Stocks of 2013 at TheStreet
13-Jun-13 07:01AM  InPlay: Sunesis Pharma announces Data and Safety Monitoring Board recommends continuation of co's VALOR Trial with no change to study conduct Briefing.com
07:00AM  Data and Safety Monitoring Board Recommends Continuation of Sunesis Pharmaceuticals' VALOR Trial With no Change to Study Conduct GlobeNewswire
12-Jun-13 02:24PM  Sunesis to Present at the Wells Fargo 2013 Healthcare Conference GlobeNewswire
11-Jun-13 07:00AM  Sunesis Pharmaceuticals Appoints Steve Carchedi to Board of Directors GlobeNewswire
01:05AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material EDGAR Online
05-Jun-13 10:00PM  Here's What This $5 Billion Hedge Fund Has Been Buying at Motley Fool
31-May-13 06:04PM  Nasdaq stocks posting largest percentage decreases AP -6.42%
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ketchum Steven BDirectorNov 08Option Exercise2.0910,50321,95184,464Apr 02 07:29 PM
Ketchum Steven BDirectorNov 08Sale5.0810,50353,36473,961Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Option Exercise2.0919,55140,86293,512Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Sale5.0319,55198,29573,961Apr 02 07:29 PM